GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eusol Biotech Co Ltd (ROCO:6652) » Definitions » EV-to-EBIT

Eusol Biotech Co (ROCO:6652) EV-to-EBIT : -17.21 (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eusol Biotech Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eusol Biotech Co's Enterprise Value is NT$842.99 Mil. Eusol Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-48.98 Mil. Therefore, Eusol Biotech Co's EV-to-EBIT for today is -17.21.

The historical rank and industry rank for Eusol Biotech Co's EV-to-EBIT or its related term are showing as below:

ROCO:6652' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.89   Med: -7.35   Max: -2.54
Current: -17.21

During the past 9 years, the highest EV-to-EBIT of Eusol Biotech Co was -2.54. The lowest was -18.89. And the median was -7.35.

ROCO:6652's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 10.2 vs ROCO:6652: -17.21

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Eusol Biotech Co's Enterprise Value for the quarter that ended in Jun. 2023 was NT$1,365.04 Mil. Eusol Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-48.98 Mil. Eusol Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -3.59%.


Eusol Biotech Co EV-to-EBIT Historical Data

The historical data trend for Eusol Biotech Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eusol Biotech Co EV-to-EBIT Chart

Eusol Biotech Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only -21.47 -27.21 -14.22 -61.07 -20.12

Eusol Biotech Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.22 - -61.07 - -20.12

Competitive Comparison of Eusol Biotech Co's EV-to-EBIT

For the Biotechnology subindustry, Eusol Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eusol Biotech Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eusol Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eusol Biotech Co's EV-to-EBIT falls into.



Eusol Biotech Co EV-to-EBIT Calculation

Eusol Biotech Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=842.992/-48.98
=-17.21

Eusol Biotech Co's current Enterprise Value is NT$842.99 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eusol Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-48.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eusol Biotech Co  (ROCO:6652) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Eusol Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-48.98/1365.038
=-3.59 %

Eusol Biotech Co's Enterprise Value for the quarter that ended in Jun. 2023 was NT$1,365.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eusol Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-48.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eusol Biotech Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Eusol Biotech Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Eusol Biotech Co (ROCO:6652) Business Description

Traded in Other Exchanges
N/A
Address
Minsheng E. Road, 6th Floor, No.135, Sec.3, Songshan District, Taipei, TWN, 10546
Eusol Biotech Co Ltd is a Taiwan based company that invests in developing new drugs to fulfill unmet medical needs. Its pipeline products include ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with the sedative effect.

Eusol Biotech Co (ROCO:6652) Headlines

No Headlines